← All trials
NCT04606576
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- Oct 28, 2020
- Last posted
- Nov 2, 2020
- Enrollment
- 675
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oramed Pharmaceutical Inc.Lead sponsor
- Oramed Pharmaceutical Inc.Study director
- IntegriumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.